GlassScriptPhysician profile
Jackquelin Perez
NPI 1902113269
$2,406.49
in general payments reported to CMS, 2019-2025
29 companies · $351 in 2025
The $351 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $100 · 2020: $163 · 2021: $314 · 2022: $440 · 2023: $607 · 2024: $432 · 2025: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,389.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $618.71 | 2022-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $361.15 | 2019-2024 | Lo Loestrin Fe |
| Bayer Healthcare Pharmaceuticals INC. | $230.17 | 2020-2025 | |
| Myovant Sciences INC. | $162.89 | 2021-2022 | |
| Organon LLC | $138.06 | 2021-2025 | Nexplanon, Jada System |
| Mayne Pharma Commercial LLC | $87.92 | 2022-2024 | |
| Exeltis, USA INC. | $80.82 | 2020-2025 | Slynd |
| Hologic Sales and Service, LLC | $75.38 | 2019-2024 | Aptima, Thinprep 2000 Processor |
| Merck Sharp & Dohme LLC | $61.31 | 2020-2025 | Gardasil 9, Gardasil |
| Exact Sciences Corporation | $51.55 | 2025 | Cologuard Collection Kit |
| Shield Therapeutics INC | $47.63 | 2024-2025 | |
| Biogen, INC. | $46.07 | 2025 | Zurzuvae |
| Agile Therapeutics, INC. | $43.22 | 2022-2023 | Twirla |
| Novo Nordisk INC | $42.08 | 2024 | Wegovy |
| Scynexis, INC. | $34.65 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $33.52 | 2022-2023 | Vpriv |
| Therapeuticsmd, INC. | $31.10 | 2021-2022 | |
| Myriad Women'S Health, INC. | $30.64 | 2023 | Myrisk |
| Mycovia Pharmaceuticals, INC. | $29.27 | 2023 | Vivjoa |
| Axonics, INC. | $28.50 | 2023 | Axonics |
| Stryker Corporation | $26.44 | 2021 | |
| Optumhealth Care Solutions, LLC | $23.77 | 2023 | Vivify Health Care Team Portal, Zyno Solutions |
| Evofem Biosciences, INC. | $23.07 | 2021 | |
| Mylan Pharmaceuticals INC. | $19.19 | 2022 | |
| Sumitomo Pharma America, INC. | $19.09 | 2023 | Myfembree |
| Medtronic, INC. | $18.51 | 2024 | Ligasure |
| Amag Pharmaceuticals, INC. | $14.66 | 2019 | |
| Coopersurgical, INC. | $13.74 | 2019 | |
| Aspira Women'S Health INC | $13.38 | 2024 | Ova1 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jackquelin Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.